BCRX
Price
$7.07
Change
-$0.26 (-3.55%)
Updated
Apr 4, 12:02 PM (EDT)
Capitalization
1.53B
27 days until earnings call
PRTA
Price
$10.78
Change
-$0.55 (-4.86%)
Updated
Apr 4, 10:44 AM (EDT)
Capitalization
609.32M
33 days until earnings call
Ad is loading...

BCRX vs PRTA

Header iconBCRX vs PRTA Comparison
Open Charts BCRX vs PRTABanner chart's image
BioCryst Pharmaceuticals
Price$7.07
Change-$0.26 (-3.55%)
Volume$3.68K
Capitalization1.53B
Prothena
Price$10.78
Change-$0.55 (-4.86%)
Volume$100
Capitalization609.32M
BCRX vs PRTA Comparison Chart
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. PRTA commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and PRTA is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (BCRX: $7.33 vs. PRTA: $11.32)
Brand notoriety: BCRX: Notable vs. PRTA: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 90% vs. PRTA: 110%
Market capitalization -- BCRX: $1.53B vs. PRTA: $609.32M
BCRX [@Biotechnology] is valued at $1.53B. PRTA’s [@Biotechnology] market capitalization is $609.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whilePRTA’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • PRTA’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than PRTA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 5 TA indicator(s) are bullish while PRTA’s TA Score has 3 bullish TA indicator(s).

  • BCRX’s TA Score: 5 bullish, 5 bearish.
  • PRTA’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than PRTA.

Price Growth

BCRX (@Biotechnology) experienced а -6.39% price change this week, while PRTA (@Biotechnology) price change was -12.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.53%. For the same industry, the average monthly price growth was -16.33%, and the average quarterly price growth was -18.08%.

Reported Earning Dates

BCRX is expected to report earnings on May 01, 2025.

PRTA is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-10.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($1.53B) has a higher market cap than PRTA($609M). BCRX YTD gains are higher at: -2.527 vs. PRTA (-18.267). BCRX has higher annual earnings (EBITDA): 12.8M vs. PRTA (-153.67M). PRTA has more cash in the bank: 471M vs. BCRX (321M). PRTA has less debt than BCRX: PRTA (10.8M) vs BCRX (809M). BCRX has higher revenues than PRTA: BCRX (451M) vs PRTA (135M).
BCRXPRTABCRX / PRTA
Capitalization1.53B609M251%
EBITDA12.8M-153.67M-8%
Gain YTD-2.527-18.26714%
P/E RatioN/AN/A-
Revenue451M135M334%
Total Cash321M471M68%
Total Debt809M10.8M7,491%
FUNDAMENTALS RATINGS
BCRX vs PRTA: Fundamental Ratings
BCRX
PRTA
OUTLOOK RATING
1..100
1469
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
63
Fair valued
PROFIT vs RISK RATING
1..100
7196
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
5485
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
4914

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (29) in the Biotechnology industry is somewhat better than the same rating for PRTA (63). This means that BCRX’s stock grew somewhat faster than PRTA’s over the last 12 months.

BCRX's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as PRTA (96). This means that BCRX’s stock grew similarly to PRTA’s over the last 12 months.

PRTA's SMR Rating (94) in the Biotechnology industry is in the same range as BCRX (100). This means that PRTA’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (54) in the Biotechnology industry is in the same range as PRTA (85). This means that BCRX’s stock grew similarly to PRTA’s over the last 12 months.

PRTA's P/E Growth Rating (94) in the Biotechnology industry is in the same range as BCRX (100). This means that PRTA’s stock grew similarly to BCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXPRTA
RSI
ODDS (%)
Bullish Trend 1 day ago
89%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
72%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 12 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Ad is loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AMADX35.95N/A
N/A
American Century Discplnd Cor Val A
CCPIX45.64N/A
N/A
Calvert Mid-Cap I
GSAGX21.72N/A
N/A
Goldman Sachs China Equity A
JVAYX38.23N/A
N/A
JPMorgan Value Advantage R6
AWWIX14.22N/A
N/A
CIBC Atlas International Growth Instl